HC Wainwright Has Optimistic Opinion of VERA FY2026 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA) – Analysts at HC Wainwright upped their FY2026 earnings estimates for shares of Vera Therapeutics in a note issued to investors on Friday, November 6th. HC Wainwright analyst A. He now expects that the company will earn ($5.94) per share for the year, up from their previous estimate of ($6.52). HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($6.45) per share. HC Wainwright also issued estimates for Vera Therapeutics’ Q4 2026 earnings at ($1.43) EPS, Q1 2027 earnings at ($1.39) EPS, Q3 2027 earnings at ($0.96) EPS, Q4 2027 earnings at ($0.61) EPS and FY2027 earnings at ($4.24) EPS.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($1.30) EPS for the quarter, beating the consensus estimate of ($1.62) by $0.32. The firm had revenue of $10.28 million during the quarter, compared to analyst estimates of $3.42 million.

Several other research analysts have also recently issued reports on the company. Raymond James Financial set a $87.00 price target on Vera Therapeutics in a research note on Friday. Wedbush cut their price objective on shares of Vera Therapeutics from $34.00 to $29.00 and set a “neutral” rating on the stock in a research note on Friday. Leerink Partners started coverage on shares of Vera Therapeutics in a report on Monday, October 12th. They issued a “market perform” rating and a $34.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Thursday, October 15th. Finally, JPMorgan Chase & Co. increased their target price on shares of Vera Therapeutics from $76.00 to $83.00 and gave the company an “overweight” rating in a research report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $74.93.

Vera Therapeutics Stock Up 2.8%

VERA opened at $30.61 on Tuesday. The stock’s 50 day moving average price is $31.53 and its 200 day moving average price is $36.60. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92. The stock has a market cap of $2.21 billion, a P/E ratio of -5.19 and a beta of 1.07. Vera Therapeutics has a 12 month low of $26.00 and a 12 month high of $56.05.

Hedge Funds Weigh In On Vera Therapeutics

Several hedge funds have recently made changes to their positions in the business. Pictet Asset Management Holding SA boosted its holdings in Vera Therapeutics by 47.2% during the third quarter. Pictet Asset Management Holding SA now owns 1,839,245 shares of the company’s stock worth $59,397,000 after buying an additional 589,831 shares in the last quarter. Readystate Asset Management LP bought a new stake in shares of Vera Therapeutics during the 2nd quarter worth $12,663,000. Renaissance Technologies LLC boosted its stake in shares of Vera Therapeutics by 136.5% during the 1st quarter. Renaissance Technologies LLC now owns 457,300 shares of the company’s stock worth $18,397,000 after acquiring an additional 263,900 shares in the last quarter. Engineers Gate Manager LP grew its holdings in shares of Vera Therapeutics by 1,579.2% in the 2nd quarter. Engineers Gate Manager LP now owns 108,139 shares of the company’s stock worth $4,640,000 after acquiring an additional 101,699 shares during the last quarter. Finally, Candriam S.C.A. grew its holdings in shares of Vera Therapeutics by 21.5% in the 3rd quarter. Candriam S.C.A. now owns 568,560 shares of the company’s stock worth $18,426,000 after acquiring an additional 100,461 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total value of $684,500.00. Following the completion of the sale, the chief executive officer directly owned 235,244 shares of the company’s stock, valued at approximately $8,704,028. This represents a 7.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company developing treatments for immune-mediated diseases. Headquartered in Brisbane, California, the company focuses on therapies intended to address underlying immune processes involved in conditions with significant unmet medical needs.

Its lead investigational candidate, atacicept, is a fusion protein designed to inhibit BAFF and APRIL, proteins that support B-cell activity and antibody production. Vera is studying atacicept for IgA nephropathy and other autoimmune diseases.